Health Care Compliance Association's (HCCA) West Coast Regional Annual Conference
June 27, 2008
Foley Partners Shirley Morrigan and Cheryl Wagonhurst will be speaking at the Health Care Compliance Association’s (HCCA) West Coast Regional Annual Conference, June 27, 2008 in Los Angeles, California.
Ms. Morrigan is speaking from 10:15 a.m. – 11:15 a.m. Her session is titled: “Key California Health Laws of Interest to the Compliance Officer.” Topics that will be covered include:
- AB 632 Medical Staff Whistleblower Protection
- AB 682 Changes in Consent Requirements for HIV/AIDS Testing
- A potpourri of other legislation related to compliance
Ms. Wagonhurst is speaking from 3:45 p.m. – 4:45 p.m. with Rory Jaffe, Executive Director – Medical Services, Office of the President, University of California. Their session is titled “Quality of Care and Compliance.” Topics that will be covered include:
- How to integrate quality into your compliance program
- Recently issued OIG/AHLA guidance for Boards of Directors
- When to consider using outside independent review organizations when peer review is not working
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.